Berenberg Bank set a €85.00 ($100.00) price objective on MorphoSys AG (ETR:MOR) in a report released on Wednesday morning. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the company. Deutsche Bank AG set a €90.00 ($105.88) target price on MorphoSys AG and gave the company a buy rating in a research report on Monday. Oddo Bhf set a €81.00 ($95.29) target price on MorphoSys AG and gave the company a buy rating in a research report on Thursday, October 26th. Goldman Sachs Group, Inc. (The) set a €72.00 ($84.71) target price on MorphoSys AG and gave the company a neutral rating in a research report on Wednesday, October 25th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the company a buy rating in a research report on Tuesday, October 24th. Finally, J P Morgan Chase & Co set a €85.00 ($100.00) target price on MorphoSys AG and gave the company a buy rating in a research report on Friday, October 6th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of €79.00 ($92.94).

WARNING: “MorphoSys AG (MOR) Given a €85.00 Price Target at Berenberg Bank” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/morphosys-ag-mor-given-a-85-00-price-target-at-berenberg-bank/1673946.html.

About MorphoSys AG

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.